There is a ritual in cancer wards all over this country. When a patient finishes treatment, they ring a bell. It means: I made it. I got to the other side. Family cheers, nurses clap, and for one bright moment the fight is behind them.

Julie Breneiser will never ring that bell. Neither will her son. Neither will her daughter. Not because their treatment failed — but because, for them, the treatment never ends.

Julie lives with Gorlin syndrome, a rare genetic condition most people have never heard of. By her own count, she has had around a thousand basal cell carcinomas. A thousand. And as one of her doctors once told her, in a sentence she has never forgotten: you will never be cancer free.

What Gorlin syndrome actually is

Basal cell carcinoma is the most common cancer in the world — about five million new cases in the United States alone every year. For most people who get it, it's a spot, a quick procedure, a small scar, and a story with an ending. That's why it's sometimes called "the good cancer."

Gorlin syndrome — also known as nevoid basal cell carcinoma syndrome — turns that story inside out. It's a rare inherited disorder, and as Julie explains it, the most burdensome thing it does is cause basal cell carcinomas to appear again and again and again, often beginning in childhood. Many in her community develop hundreds or thousands over a lifetime. The syndrome can affect nearly every system in the body — it's associated with jaw cysts, and children can be born with larger heads and mild hydrocephalus — but it is the relentless march of skin cancers that defines daily life.

It's genetic, and it's what's called autosomal dominant: each child of a parent with Gorlin syndrome has a fifty-percent chance of inheriting it. For about a third of people, though, it appears out of nowhere, through a spontaneous mutation with no family history at all. That was Julie. There was no Gorlin syndrome before her — and then there was, and then it was in her children.

A mother, twice over

Julie is both patient and caregiver, and she is quick to say which comes first. "I was a physician assistant, so I thought I knew my stuff," she says. "But I'm a patient and a human being first."

Her daughter was formally diagnosed at seven, after a large jaw cyst. Her son was diagnosed around the same age. Both had shown early signs as infants. It is one thing to carry a disease you understand from the inside. It is another to watch your own children inherit it — to know that the thing you cannot outrun has been passed down, and that they will spend their childhoods in dermatologists' offices and operating chairs.

The treatment itself is a life sentence of maintenance. Julie's standard is Mohs surgery from the neck up and surgical excisions below; she has used a topical chemotherapy cream on her scalp — six weeks of oozing lesions, bandages twice a day, and then, finally, hair that grew back over skin that stayed clear for years. It works, but it costs. And one option that helps many other skin-cancer patients is off the table entirely: for people with Gorlin syndrome, radiation is contraindicated. As Julie puts it, ionizing radiation is like "pouring fuel on the fire" — it doesn't calm the disease, it sets it off, triggering even more cancers. So the toolbox is smaller than it looks, and every tool leaves a mark.

Now imagine that across a childhood. Imagine it across a thousand.

The treatment that was almost theirs

Here is the part that is hardest to sit with. Julie's community has come right up to the edge of relief — more than once.

For years, the great hope was a topical treatment designed specifically to slow the tumor burden in Gorlin patients. In trials, people saw their skin clearing for the first time in their lives. Then the trials came up short of the endpoint the FDA generally requires — a fifty-percent improvement — and the treatments didn't move forward to approval. Julie has watched two topical medications reach that edge and slip away.

"It's like reaching for the golden apple," she says. "You take a bite — and then the apple's taken away from you." Patients who had gone from no new cancers on their faces went right back to skin-cancer surgery every three to six months. "It's a devastating loss."

And it raises a question Julie has spent years pressing on regulators: whose definition of success are we using? In a disease this rare and this relentless, a thirty-percent reduction would be enormous. "I've had over a thousand," she says. "If I knew there was something that would let me only have to deal with seven hundred in my lifetime — that's a big difference." The trial called that a failure. She calls it three hundred surgeries she wouldn't have needed.

A community that doesn't wait quietly

Julie helps lead the Gorlin Syndrome Alliance, a nonprofit that provides information, support, and — increasingly — a seat at the table where decisions get made. In 2020 and 2021, the Alliance held a patient listening session and a patient-focused drug development meeting to put their burden on the record with the FDA, complete with a photo gallery of patients of every age, so that no one deciding the fate of a treatment could talk about "endpoints" without seeing the faces on the other side of the number.

That refusal to wait quietly is exactly how the next chapter began. In the fall of 2025, Julie read about an investigational skin-cancer patch in development and did something disarmingly simple: she found the company's CEO on LinkedIn and sent a letter. We're a community heavily burdened with basal cell carcinomas. We'd love to learn more. He wrote back. They met. And a treatment being tested on patients who had only ever had one or two skin cancers is now being discussed for the people who have had a thousand.

It is important to be clear-eyed here: that patch is still investigational. It is not approved. Nothing is promised. This is a community that has learned, the hard way, that golden apples can be taken away. But the conversation is real, and the door is open — and for a group used to closed doors, that matters.

What Julie hopes for

Ask her what she's reaching for, and she doesn't talk about statistics. She talks about her kids.

"Nobody wants more scars," she says. "I think about my thirty-something kids and their scars… Wouldn't it be marvelous if the work they've had done could have been done with a topical that didn't leave a scar on their nose, a scar on their temple?"

Wouldn't it be marvelous.

If you or someone you love lives with Gorlin syndrome, you are not alone, and there is a community ready to stand with you. Learn more, find support, and add your voice at gorlinsyndrome.org.

And for the rest of us — the next time someone calls basal cell "the good cancer," remember Julie. The most common cancer in the world is, for some people, one of the rarest and hardest diseases there is. There is a person behind every one of those five million cases. And some of them will be fighting for the rest of their lives.

This story is drawn from Julie Breneiser's conversation on Episode 2 of the State of the Patient Podcast. Listen to the full episode: [LISTEN LINK].